{
  "nctId": "NCT05998265",
  "briefTitle": "A Randomised, Controlled, Open-Label, Multi-Centre Study to Evaluate the Efficacy of FeetMe® Home-Bases Rehabilitation Program in Comparison to Conventional Physiotherapy in Patients With Parkinson's Disease Using Connected Insoles",
  "officialTitle": "A Randomised, Controlled, Open-Label, Multi-Centre Study to Evaluate the Efficacy of FeetMe® Home-Bases Rehabilitation Program in Comparison to Conventional Physiotherapy in Patients With Parkinson's Disease Using Connected Insoles",
  "protocolDocument": {
    "nctId": "NCT05998265",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2023-05-09",
    "uploadDate": "2023-08-03T10:14",
    "size": 7352052,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT05998265/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 150,
    "enrollmentType": "ESTIMATED"
  },
  "timeline": {
    "startDate": "2023-11",
    "completionDate": "2025-11",
    "primaryCompletionDate": "2025-11",
    "firstSubmitDate": "2023-08-03",
    "firstPostDate": "2023-08-18"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Written informed consent to participate in the study.\n* Male or female patients between 40 to 70 years of age, inclusive.\n* Body weight range of 40 kg to120 kg and a body mass index (BMI) of 18 to 34 kg/m2.\n* Diagnosis of Idiopathic Parkinson's disease (PD) according to UK Brain Bank Criteria (2/3 symptoms), with Hoehn and Yahr (H\\&Y) staging level 2, 2.5 or 3.\n* Disease onset of at least 3 years prior to enrolment.\n* Patients with a history of 50% of levodopa responsiveness based on motor signs.\n* On stable treatment of PD medication for at least 30 days before screening and with no expected major changes during the first 3 months of the study.\n* Prescription for physiotherapy available.\n* Ability to walk without aid for at least 6 minutes.\n* Shoe size between 35 - 46 (European Standard).\n* Intact skin on feet.\n* Adequate visual and auditory acuity to perform the rehabilitation program and the assessments in the Investigator's judgement.\n* Comfortable with the use of a smartphone. If assistance is required for the use of FeetMe technology, a caregiver or volunteer is fully available to assist the patient.\n* Willingness to be regularly contacted via phone-calls.\n* Willingness to suspend conventional physiotherapy treatment and start the FeetMe rehabilitation program, if applicable.\n* French speaker.\n\nExclusion Criteria:\n\n* Medical history indicating a Parkinsonian syndrome other than idiopathic PD.\n* Unable to walk without walking aid or presence of an injury preventing the patient to walk.\n* Any relevant comorbidity or vestibular/visual dysfunctions limiting locomotion or balance.\n* Clinically significant comorbidities which in the judgement of the investigator may preclude the reliable gait assessment of the patient.\n* Patients with poor wound healing or broken skin on the feet.\n* Patients with foot implants.\n* Montreal Cognitive Assessment (MoCA) score ≤ 24/30.\n* Patients with dementia.\n* Patients with apathy.\n* Participation in another clinical trial with an investigational drug/ therapeutic within the three months before screening and during the study, unless agreed by the Sponsor.\n* Patients who had Lee Silverman Voice Treatment (LSVT) Big therapy within the past 12 months or have it planned during the course of the study.\n* Patients with Deep Brain Stimulation planned during the first 12 weeks of the study.\n* Patients with pacemakers.\n* Patients performing vigorous exercise \\> three times a week, 30 mins or more per session.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "40 Years",
    "maximumAge": "70 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Gait velocity",
        "description": "Change from baseline to Week 12 (Visit 3) in gait velocity (cm/s) assessed during the 6 Minutes Walk-Test (6MWT).",
        "timeFrame": "Week 12"
      }
    ],
    "secondary": [
      {
        "measure": "Stance time variability",
        "description": "Change from baseline to Week 12 (Visit 3) in Stance Time Variability assessed during the 6MWT.",
        "timeFrame": "Week 12"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 1,
      "otherCount": 0,
      "totalCount": 2
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 29,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:29:46.234Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}